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Available online 3 April 2019Background: We have recently reported that activation of cannabinoid type 2 receptors (CB2Rs) reduces
dopamine (DA) neuron excitability in mouse ventral tegmental area (VTA). Here, we elucidate the underlying
mechanisms.
Methods: Patch-clamp recordings were performed in mouse VTA slices and dissociated single VTA DA neurons.
Findings: Using cell-attached recording in VTA slices, bath-application of CB2R agonists (JWH133 or ﬁve other
CB2R agonists) signiﬁcantly reduced VTA DA neuron action potential (AP) ﬁring rate. Under the patch-clamp
whole-cell recordingmodel, JWH133 (10 μM)mildly reduced the frequency ofminiature excitatory postsynaptic
currents (mEPSCs) but not miniature inhibitory postsynaptic currents (mIPSCs). JWH133 also did not alter
evoked EPSCs or IPSCs. In freshly dissociated VTA DA neurons, JWH133 reduced AP ﬁring rate, delayed AP initi-
ation and enhanced AP after-hyperpolarization. In voltage-clamp recordings, JWH133 (1 μM) enhanced M-type
K+ currents and this effect was absent in CB2
−/−mice and abolished by co-administration of a selective CB2R an-
tagonist (10 μM, AM630). CB2R-mediated inhibition in VTA DA neuron ﬁring can be mimicked by M-current
opener (10 μM retigabine) and blocked by M-current blocker (30 μM XE991). In addition, enhancement of neu-
ronal cAMP by forskolin (10 μM) reduced M-current and increased DA neuron ﬁring rate. Finally, pharmacolog-
ical block of synaptic transmission byNBQX (10 μM), D-APV (50 μM) and picrotoxin (100 μM) inVTA slices failed
to prevent CB2R-mediated inhibition, while intracellular infusion of guanosine 5'-O-2-thiodiphosphate (600 μM,
GDP-β-S) through recording electrode to block postsynaptic G-protein function prevented JWH133-induced re-
duction in AP ﬁring.
Interpretation: Our results suggest that CB2Rs modulate VTA DA neuron excitability mainly through an intrinsic
mechanism, including a CB2R-mediated reduction of intracellular cAMP, and in turn enhancement of M-type
K+ currents.
Fund: This research was supported by the Barrow Neuroscience Foundation, the BNI-BMS Seed Fund, and CNSF
(81771437).
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The CB2R is a G-protein-coupled receptor that was cloned in 1993
[5]. Since then, the expression and function of CB2Rs in the brain hasnd Neurobiology, St. Joseph's
stitute, 350 W Thomas Road,
. This is an open access article underbeen debated. Early studies suggested that CB2Rs were absent in the
brain because CB2 mRNA transcripts were not detected in brain tissues
[1–4]. Based on these ﬁndings, the CB2R has been considered as a
“peripheral” cannabinoid receptor [5–7]. Recently, this concept has
been challenged by the identiﬁcation of CB2R mRNA and receptor pro-
teins throughout the central nervous system (CNS) [8,9], including the
cerebral cortex [10], hippocampus [11], striatum [12], amygdala and
brainstem [12–17]. Immunoblot and immunohistochemistry (IHC)
assay also detect CB2R-immunoreactivity or immunostaining in variousthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Cannabis sativa (marijuana) is a fibrous flowering plant that natu-
rally produces an abundant variety of molecules, some with psy-
choactive effects. At least 4% of the world's adult population
uses cannabis annually, making it one of the most frequently
used illicit drugs in the world. The psychoactive effects of canna-
bis are mediated primarily through two cannabinoid receptor
(CBR) subtypes, CB1R and CB2R. The prevailing view is that
CB1Rs are mainly expressed in central neurons while CB2Rs are
predominantly expressed in peripheral immune cells. However,
this traditional view has been challenged by strong emerging evi-
dence that shows CB2Rs are moderately expressed and function
in specific brain areas. New evidence has demonstrated that
brain CB2Rs mediate important modulations in animal cocaine-
seeking behaviors (Xi et al., Nature of Neuroscience, Jul 24;14
[9]:1160-6, 2011), suggesting that these receptors may exist in
the brain regions that regulate drug addiction. Recently,we further
confirmed that functional CB2Rs are expressed in mouse ventral
tegmental area (VTA) DA neurons, and activation of VTA CB2Rs
reduces neuronal excitability and cocaine-seeking behavior
(Zhang et al., PNAS 111 [46]:E5007-15, 2014). However, the
mechanisms and the CB2R-G protein intracellular signaling that
underlies these VTA CB2R-mediated modulations are unknown.
Added value of this study
In this paper, we elucidate the underlyingmechanisms. Using cell-
attached recording in VTA slices, bath-application of a CB2R ago-
nist (JWH133) inhibited VTA DA neuron firing in a concentration-
dependent manner. In addition to JWH133, five other CB2R ago-
nists exhibited similar inhibition. Under the patch-clamp whole-
cell recording model, JWH133 (10 μM) inhibited miniature excit-
atory postsynaptic currents (mEPSCs) but not miniature inhibitory
postsynaptic currents (mIPSCs). However, JWH133 did not in-
hibit evoked EPSCs or IPSCs. In freshly dissociated VTA DA neu-
rons, JWH133 reduced the action potential (AP) firing rate,
delayed AP initiation and enhanced AP after-hyperpolarization. In
voltage-clamp recordings, M-type K+ currents were enhanced
by JWH133. This effect was absent in CB2
−/− mice and abolished
by co-administration of a selective CB2R antagonist (AM630). In
addition, CB2R-mediated inhibition in VTA DA neuron firing can
be mimicked by an M-current opener and blocked by an M-
current blocker. Finally, CB2R-cAMP signaling plays a role in mod-
ulating DA neuron excitability since enhancement of cAMP by
forskolin reduced M-current and increased DA neuron firing rate.
Implications of all the available evidence
These results suggest that CB2Rsmodulate VTADA neuron excit-
ability through both synaptic and intrinsic mechanisms, including
a reduction in presynaptic glutamate release and enhancement
of postsynaptic neuronal M-currents. This work provides new in-
sights into understanding the impact of brain CB2Rs in a variety
of DA system associated disease pathogenesis and potential
therapeutics.
226 Z. Ma et al. / EBioMedicine 42 (2019) 225–237brain regions [16,18–23]. Consistent with these ﬁndings, we reported
that brain CB2Rs modulate cocaine self-administration, cocaine-
enhanced locomotion and extracellular dopamine (DA) levels in the nu-
cleus accumbens in mice [24]. This ﬁnding was further supported by a
study where mice over-expressing CB2Rs exhibit a signiﬁcantly lowerlevel of cocaine self-administration and cocaine-enhanced locomotion
compared to wild type (WT) mice [22]. Recently, we identiﬁed func-
tional CB2R expression in mouse VTA DA neurons, and selective activa-
tion of these CB2Rs reduced DA neuronal excitability in vitro and in vivo
preparations [25].More recently, Stempel et al. reported that CB2Rsme-
diated a cell type-speciﬁc plasticity in the hippocampal CA3 neurons
[11]. However, the cellular and molecular mechanisms underlying
CB2R modulation of VTA DA neuronal excitability are poorly
understood.
In the present study, we systematically investigated synaptic and in-
trinsic ionic channel mechanisms possibly underlying CB2R modulation
of VTADA neurons using patch-clamp recordings.We found that activa-
tion of VTA CB2Rs reduced the frequency of mEPSCs but not mIPSCs in
DA neurons. By using a perforated patch-clamp recording in acutely dis-
sociated VTA DA neurons, a simple single cell model without intact pre-
synaptic connections, we found that JWH133 reduced DA neuron action
potential (AP) ﬁring rate, prolonged AP initiation, enhanced after-
hyperpolarization, and enhanced M-type K+ channel currents. In addi-
tion, we determined whether the presynaptic (reduction of mEPSC fre-
quency) or postsynaptic (intrinsic) or both contribute to JWH133-
induced reduction in AP ﬁring, and found that the intrinsic mechanism
such as enhancement of M-current, contributes to CB2R–mediated re-
duction of VTA DA neuronal excitability, which may play an important
role in the regulation of DA-associated behaviors and diseases.
2. Methods and materials
2.1. Animals
Male wild-type (WT) and Zimmer strain CB2−/− mice [6,7] with
C57BL/6J genetic backgrounds were bred at Barrow Neurological Insti-
tute. Genotyping was performed in our laboratory before experiments
were begun. All experiments were in compliance with the Guide for
the Care and Use of Laboratory Animals and experimental protocol has
been approved by IACUC of Barrow Neurological Institute. When we
tested the effects of CB2R agonist on VTA DA neurons using CB2−/−
mice, the littermateWTmicewere used as the control. All experimental
procedures were approved by the Institutional Animal Care and Use
Committee at the Barrow Neurological Institute and by the Animal
Ethics Committee of Qingdao University.
2.2. VTA slice preparation
Mice (14–31 days old) were used as previously described [26–28].
Brieﬂy, mice were housed under standard conditions at 22–24 °C and
50–60% humidity under a 12 h light/dark cycle. On the experimental
day, mice were anesthetized (isoﬂurane USP) and then sacriﬁced by
decapitation. Horizontal (or coronal) midbrain slices (250 μm) were
cut using a vibratome 1000 (Vibratome 1000 plus; Jed Pella Inc., Red-
ding, CA) to include the VTA. Slices were prepared in an ice-cold,
sucrose-based, artiﬁcial cerebrospinal ﬂuid containing (in mM):
212.7 sucrose, 5 KCl, 1.25 NaH2PO4, 3 MgCl2, 1 CaCl2, 26 NaHCO3,
and 10 glucose. The slices were then incubated for at least 1 h in a
pre-incubation chamber (Warner Ins., Holliston, MA) at room temper-
ature (22–24 °C) in conventional artiﬁcial cerebrospinal ﬂuid contain-
ing (ACSF, in mM): 124 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2, 1.25 NaH2PO4,
26 NaHCO3 and 10 glucose. The ACSF was continuously saturated
with 95% O2 and 5% CO2.
2.3. Cell-attached patch-clamp recordings in VTA slices
For slice patch recordings, horizontal or coronalmidbrain slices (250
μm thickness) were prepared from 14- to 31-day old mice (WT and
CB2−/−) mice as described previously [28]. To maintain an intact intra-
cellular environment, we employed a cell-attached mode of patch re-
cording. Thus, we were able to measure stable extracellular action
Fig. 1. Identiﬁcation of VTA DA neurons from patch-clamp recording in VTA slice. (a) In patch-clamp cell-attached recording mode, bath-application of 100 nM quinpirole (dopamine D2
receptor agonist) inhibited ﬁring rate of DAergic neurons. (b) Under whole-cell recording mode, DA neurons exhibited hyperpolarizing pulse-activated currents (H-current, left traces)
whereas GABAergic neurons usually did not express H-currents (Right traces). (c) After patch recording, the biocytin (2 mg/ml) was delivered into recorded neuron (left panel).
Tyrosine hydroxylase (TH) staining was performed post hoc and labels DA neurons (middle and right panels).
227Z. Ma et al. / EBioMedicine 42 (2019) 225–237potential (AP) ﬁring for hours. The recording pipette was ﬁlled with in-
tracellular solution containing in mM: 140 potassium gluconate, 5 KCl,
10 HEPES, 0.2 EGTA, 2 MgCl2, 4 MgATP, 0.3 Na2GTP and 10 Na2-
phosphocreatine (pH 7.3 with KOH). After patch recording, we con-
verted from cell-attached mode to conventional whole-cell recording
to identify the neuronal phenotype of the recorded neuron according
to standard electrophysiological, pharmacological and immunostaining
criteria as described previously [28,29]. Brieﬂy, in this study, we mostly
recorded DA neurons from lateral VTA, which demonstrated a low ac-
tion potential (AP) ﬁring rate (1–3 Hz), large H-current, and TH positive
reaction by immunostaining (Fig. 1A-C).We have analyzed 12 VTA neu-
rons (from 12 mice), under the cell-attached recording mode to record
extracellular AP ﬁring, the averaged AP duration was 2.34 ± 0.07 ms,
the averaged ﬁring rate was 1.65 ± 0.14 Hz, and after perfusion of
100 nM quinpirole for 10 min, the AP ﬁring rate was reduced to 0.53
± 0.08 Hz (paired t-test p b 0.0001). After washout of quinpirole for
10 min, AP ﬁring rate recovered to 1.40 ± 0.12 Hz (quinpirole washout
p b 0.0001). In addition, we have examined the effects of JWH133 on H-
currents of DA neurons in mouse VTA slices. In 4 cells tested (from 2
mice), the amplitudes of H-currents (hyperpolarizing from −60 to
−120 mV) before and after exposure of 10 μM JWH133 for 10 min
were 166.0 ± 24.3 pA and 161.3 ± 11.2 pA (paired t-test, p = 0.86).
These results suggest that acute application of 10 μM JWH133 to VTA
slices did not alter H-current.2.4. Miniature or evoked excitatory/inhibitory postsynaptic currents
(mEPSCs/mIPSCs, eEPSCs/eIPSCs) in VTA slices
To determine whether brain CB2Rs modulate presynaptic glutamate
or GABA release, thereby altering postsynaptic DA neuronal activity, we
recorded mEPSCs in the presence of TTX (a voltage-dependent Na+
channel blocker, 1 μM), D-APV (a NMDA receptor antagonist, 50 μM)
and picrotoxin (a selective GABAA receptor antagonist, 100 μM), or
mIPSCs in the presence of TTX, NBQX (an AMPA receptor antagonist,
10 μM) andD-APV (50 μM) inVTADAneurons. In addition,we recorded
electrical stimulation-evoked EPSCs (eEPSCs) or -evoked IPSCs (eIPSCs)
in the absence of TTX to determine whether JWH133 alters eEPSCs or
eIPSCs in VTA DA neurons.2.5. Patch-clamp recording from single dissociated VTA DA neurons
Perforated-patch whole-cell recording techniques were employed
[30,31]. Compared to performing conventional whole-cell recordings,
this approach was crucial to obtain stable nicotinic responses from dis-
sociated VTA neurons, presumably due to minimal perturbation of the
intracellular environment. Pipettes (3–5 MΩ) used for perforated-
patch recordings were ﬁlled with intracellular recording solution,
which contained (in mM): 140 K-gluconate, 10 KCl, 5 MgCl2, and 10
HEPES; pH 7.2 (with Tris-OH) freshly supplemented before use with
amphotericin B to 200 μg/mL from a 40 mg/mL DMSO stock. The liquid
junction potential was 14 mV and calculated using Clamplex 9.2 (Axon
Instruments, Foster City, CA), and corrections were made for junction
potentials post-hoc. After tight seal (N2 GΩ) formation, about
5–20 min was required for conversion to the perforated-patch mode,
and an access resistance of b60 MΩ was accepted to start the experi-
ments. Series resistance was not compensated in this study. Data were
acquired at 10 kHz, ﬁltered at 2 kHz, digitized on-line (Digidata 1440 se-
ries A/D board, Axon Instruments), and displayed and stored on a PC
computer. Rapid application of drugs was performed using a
computer-controlled “U-tube” system [30]. Periods of drug exposure
are speciﬁed in the text and ﬁgures or legends. All experiments were
performed at room temperature (21 ± 1 °C). To enable identiﬁcation
of single, dissociated VTA neurons, cells were labeled with biocytin
(Sigma-Aldrich, St. Louis, MO; 2.0 mg/mL in the recording electrode)
in some experiments. After conversion from perforated to a conven-
tional whole-cell recording mode, the dye was injected into the cyto-
plasm by a pulse (200 ms, 0.5 Hz) of depolarizing current (1.0 nA) for
3 min. Labeled cells were visualized using epiﬂuorescence microscopy
(see detail in our recent publication) [25].2.6. Data analyses and statistics
All data are presented as means (± S.E.M.). One-way or two-way
analysis of variance (ANOVA) was used to analyze the signiﬁcance of
the effects of JWH133 or other drugs on neuronal ﬁring. Individual
group comparisons were carried out using the Student Newman-Keuls
or Tukey method. In addition, paired (or unpaired) t-tests were also
Fig. 2. Activation of VTA CB2Rs reduced VTA DA neuron ﬁring rate. In VTA slices, cell-attached recording showed the typical traces of extracellular action potential (AP) ﬁring before and
after JWH133 exposure (a). A time-frequency histograph (b) and Bar graph from the normalized data (c) showed that JWH133 inhibited VTA DA neuron ﬁring in a concentration-
dependent manner. (d) Comparison of the effects of JWH133 on AP ﬁring rate between horizontal and coronal VTA slices, and showed no signiﬁcant difference between these two
types of slices (e). (f) In addition to JWH133, other 6 CB2R agonists tested showed 4 of them exhibited inhibitory effects on VTA DA neurons. * p b 0.05, ** p b 0.01. (g) In control
experiments (without any drugs), cell-attached patch recording showed a stable AP ﬁring of VTA DA neurons for 20 min. (h) Mice were classiﬁed into two age groups (postnatal 16
and 30). (i) Statistical comparison of JWH133 (10 μM)-induced inhibition of VTA DA neuron ﬁring rate between these two age-groups, and showed no statistical signiﬁcance (N.S.).
228 Z. Ma et al. / EBioMedicine 42 (2019) 225–237used to analyze some electrophysiological data as described previously
[30,31].
3. Results
3.1. Activation of CB2R reduced VTA DA neuron ﬁring
Initial experiments were designed to examine the concentration-
dependent effect of CB2R agonist (JWH133) on VTA DA neuron ﬁring
using cell-attached recording mode. Fig. 2A shows a typical trace of
VTADA ﬁring before (A top trace) and during (A bottom trace) CB2R ag-
onist JWH133 exposure. Bath applications of different concentrations of
JWH133 (1, 10, 100 μM) reduced DA neuron ﬁring rate in a
concentration-dependent manner (Fig. 2B, C, One-way ANOVA, F [4,35]
= 6.97, p b 0.001). Then, we examined the effects of JWH133 on DA
neuron ﬁring from horizontal (n= 13 from 4 mice) or coronal (b = 8
from 3mice) VTA slices, and found amodest but signiﬁcantly consistent
effect on inhibition of VTA DA neuron ﬁring in both types of slice prep-
arations (One-way ANOVA, F [2,31] = 4.79, p b 0.05, Fig. 2D, E). Further,
Tukey analysis showed that compared to baseline, JWH133 inhibitedDA
fairing rate in either coronal (p b 0.05, n=8, Tukey analysis) or horizon-
tal (p b 0.05, n = 13, Tukey analysis) slices. Furthermore, we tested
whether different CB2R agonists exhibit similar inhibitory effects on
VTA DA neuron ﬁring. As shown in Fig. 2F, the CB2R agonists, GW, SER,
CB65, JWH105, Hu308 and L759656 exhibited a similar reduction of
DA ﬁring rate (One-way ANOVA, F [6,31]= 2.4, p b 0.05), but Tukey anal-
ysis showed that JWH105 and L759656 did not reach statistical signiﬁ-
cance (p N 0.05, Tukey analysis). Finally, to exclude the possibility that
JWH133-induced reduction of AP ﬁring rate was mediated by AP ﬁringrundown with time, we performed a group of control experiments, in
which, VTA DA neuronal AP ﬁring was recorded using cell-attached
patch for 20 min without any drugs. In 6 slices tested (from 3 mice),
there was no functional rundown of AP ﬁring within 20 min (Fig. 2G),
demonstrating that cell-attached recording to measure extracellular
AP ﬁring was stable. Considering the ages of mice used in this study
were between 2 and 4 weeks, we classiﬁed mice into two age groups
and compared the effects of JWH133. Group one contained 21 slices
with an average of age 16.1 ± 0.3 postnatal days and group two
contained 6 slices with an average of 30.5 ± 0.6 postnatal days. The dif-
ference of the ages between these two groups were statistically signiﬁ-
cant (p b 0.001, unpaired t-test, Fig. 2H). 10 μM JWH133 inhibited VTA
DA AP ﬁring rate in a similar rate (Fig. 2I), in group one, the inhibitory
rate was 18 ± 4% (n= 21 from 8 mice), while in group two, the inhib-
itory rate was 15 ± 3% (n= 6 from 2 mice, p= 0.59, unpaired t-test),
suggesting that during animal developing between P16 and P30, the
CB2R-mediated inhibition in VTADA neuronal ﬁring rate is not changed.
Together, these results are further consistentwith our previous ﬁndings
that activation of VTA CB2Rs reduces VTA DA neuron ﬁring rate [25].
3.2. Effects of CB2R activation on excitatory synaptic transmission in VTADA
neurons
VTADA neuron ﬁring is controlled by both presynaptic and postsyn-
aptic mechanisms. To elucidate the mechanisms underlying CB2R-
mediated reduction of VTA DA neuronal ﬁring, we tested the effects of
CB2R agonist on excitatory synaptic transmission measured by minia-
ture excitatory postsynaptic currents (mEPSCs) in DA neurons of VTA
slices. The identiﬁcation of VTA DA neurons was based on their
Fig. 3. Effects of JWH133 on excitatory synaptic transmission in VTA DA neurons.
(a) Typical traces of mEPSCs in the presence of TTX (1 μM) and picrotoxin (100 μM)
before (top trace) and after (bottom trace) JWH133 (10 μM) exposure using whole-cell
patch-clamp recording in a VTA slice. In 19 slices, cumulative probability analysis for
mEPSC inter-event interval (b) and amplitude (c) under control conditions (black
curve) and JWH133 exposure (red curve). (d) Comparison of mEPSC frequency (left
panel) and amplitude (right panel) before and after JWH133 exposure from 19 VTA
slices tested. (e) Bar graph data illustrating JWH133 signiﬁcantly reduced mEPSC
frequency, but not amplitude.
Fig. 4. Effects of JWH133 on inhibitory synaptic transmission in VTA DA neurons.
(a) Typical traces of mIPSCs in the presence of NBQX (10 μM) and D-APV (50 μM)
before (top trace) and after (bottom trace) JWH133 (10 μM) exposure using the whole-
cell patch-clamp recording in a VTA slice. (b) and (c) In 23 VTA slices, cumulative
probability analysis for mIPSC inter-event interval and amplitude under control
conditions (baseline) and JWH133 exposure. K—S Test showed that JWH133 did not
signiﬁcantly alter both mIPSC frequency (p = 0.432, b) and amplitude (p = 0.384, c).
(d) Comparison of mIPSC frequency (left panel) and amplitude (right panel) before and
after JWH133 exposure from 23 VTA slices tested. (e) Normalized bar graph data
illustrating JWH133 did not alter mIPSC frequency and amplitude.
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patch-clamp recording as described previously [25,28] and shown in
Fig. 1A-C. In 18 VTA slices tested prepared from 9WTmice, bath perfu-
sion of 10 μM JWH133 for 10 min altered mEPSCs (Fig. 3A,B), repre-
sented as reduced frequency in 14 slices (Fig. 3C,E, left panel) and
enhanced frequency in 4 slices. Averaged data showed that JWH133 re-
duced mEPSC frequency from 0.91 ± 0.19 to 0.75 ± 0.14 Hz (p= 0.03,
paired t-test, n=18, Fig. 3F, left panel). Further cumulative distribution
of mEPSC inter-event interval showed signiﬁcantly shift (K\\S test, p=
0.002). For mEPSC amplitude, JWH133 reduced amplitude in 3 slices
and enhanced amplitude in 14 slices; and no change in 1 slice (Fig. 3D,
E, right panel), and together, there was no signiﬁcant change of ampli-
tude (from 11.0 ± 0.5 to 10.6 ± 0.4 pA, p = 0.10, paired t-test, n =
18, Fig. 3F, right panel). These results suggest that acute activation of
CB2Rs shows a modest, but statistically signiﬁcant, reduction in gluta-
matergic synaptic transmission in VTA DA neurons, including reduced
presynaptic glutamate release probability.
3.3. Effects of CB2R activation on inhibitory synaptic transmission in VTADA
neurons
We then examined the effects of JWH133 on miniature inhibitory
postsynaptic currents (mIPSCs) in the presence of TTX (1 μM), NBQX
(10 μM) and D-APV (50 μM). In 23 VTA slices prepared from 11 WTmice, bath perfusion of 10 μM JWH133 for 10 min altered mIPSC fre-
quency and amplitude, represented as reduced frequency in 9 slices
and enhanced frequency in 14 slices; reduced amplitude in 8 slices
and enhancement amplitude in 14 slices; and no change in one slice.
After averaged, these data showed that after JWH133 exposure,
mIPSC frequency was 109% (109 ± 5%, p = 0.09, paired t-test, n =
23) and amplitude was 101% (101 ± 2%, p = 0.73, paired t-test, n
= 23) compared to the baseline level (Fig. 4A, E). Neither inter-
event interval nor amplitude cumulative distribution showed shift
(Fig. 4B, C). These results suggest that activation of CB2Rs exhibits lit-
tle effects on either presynaptic GABA release or postsynaptic GABAA
receptor function.3.4. Effects of CB2R activation on evoked EPSCs and IPSCs in VTA DA neurons
We also examined the effects of JWH133 on evoked EPSCs
(eEPSCs) and IPSCs (eIPSCs). In these experiments, 100 μM PTX (for
eEPSCs) or NBQX(10 μM) + APV (50 μM) (for eIPSCs) was added
into the bath solution. A bipolar tungsten stimulation electrode was
placed at ~150 μm rostral to the recording electrode and the paired
stimulation pulses with 50 ms interval were applied (Fig. 5A). The re-
sults showed that bath perfusion of 10 μM JWH133 for 10 min failed
to alter the current amplitude and the P2/P1 ratio of paired-pulse-
induced eEPSCs (Fig. 5A-C) and eIPSCs (Fig. 5D-F). These results sug-
gest that acute activation of VTA CB2Rs does not affect evoked synaptic
neurotransmitter release.
Fig. 5. Effects of JWH133 on evoked EPSCs and IPSCs in VTA DA neurons.
(a) Representative typical traces of paired-pulse (50 ms interval) stimulation-induced
eEPSCs before (left trace pair) and after (right trace pair) exposure to JWH133. Bar
graph illustrating that JWH133 (10 μM) altered neither eEPSC amplitude (b) nor P2/P1
ratio (c) in 10 VTA slices tested. (d) Representative typical traces of paired-pulse (50 ms
interval) stimulation-induced eIPSCs before (left trace pair) and after (right trace pair)
exposure to JWH133. Bar graph illustrating that JWH133 (10 μM) did not change eIPSC
amplitude (e) and P2/P1 ratio (f) in 10 VTA slices tested.
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action potentials
The data presented thus far demonstrated that a mild reduction of
presynaptic glutamatergic by acute CB2R activation. We further eluci-
dated possible intrinsic mechanisms of the CB2R-mediated modulation
in postsynaptic DA neurons. To accomplish this, we used freshly disso-
ciated single VTA DA neurons, which is a pure postsynaptic cell model
since the enzymatic treatment and mechanical dissociation remove all
presynaptic terminals/boutons from these cells [25,30,31]. Perforated
(amphotericin B) patch-clamp recording from the single dissociated
VTA DA neurons showed that bath application of 1 μM JWH133 for
1–3 min reduced AP ﬁring rate (Fig. 6A-C), prolonged AP initiation
(Fig. 6D) and enhanced the amplitude of after-hyperpolarization cur-
rent (Fig. 6E). Fig. 6F summarizes these AP alterations before, during
and after exposure to JWH133. These results suggest that, in a single
neuron model, the activation of somatodendritic CB2Rs in VTA DA neu-
rons reduces neuronal excitability likely via alterations of intrinsic ion
channels such as the M-type K+ channels.3.6. Effects of CB2R agonist on voltage-dependent M-type K
+ currents
M-channel is a voltage-gated, non-inactivating K+ channel. It is
expressed in VTA DA neurons [32] and functionally modulates neuronal
excitability [33,34]. It has been reported thatM-channels aremodulated
by multiple G-protein-coupled receptors, including CB1Rs [35].Therefore, we explored the possibility that CB2Rs may also modulate
M-currents in VTA DA neurons. M-currents were induced with a stan-
dard deactivation voltage protocol [32,36] as shown in Fig. 7A. M-
current is measured as the inward relaxation current caused by M-
current deactivation during the voltage steps. Bath-applied JWH133 (1
μM) signiﬁcantly enhanced M-currents elicited by three hyperpolariz-
ing holding potentials in dissociated VTA DA neurons in WT mice
(Fig. 7B), and this effect was reversible after JWH133 washout
(Fig. 7C). Fig. 7D shows the superimposed traces of M-currents before
and during JWH133 exposure, showing a JWH133-induced M-current
augmentation. This effect was blocked by AM630 (1 μM) and absent
in VTA DA neurons prepared from CB2−/−mice. To conﬁrm the identity
of the recorded M-current, we examined the effects of retigabine (a se-
lective M-current enhancer, 10 μM) and XE991 (a selective M-current
blocker, 30 μM) on the recorded current. Like JWH133, retigabine en-
hanced (n=5 from 3mice, p=0.02, paired t-test), but XE991 reduced
(n=8 from 4mice, p=0.003, paired t-test) the recorded currents pro-
duced by the M-current-inducing protocol, supporting the conclusion
that the recorded currents were, indeed, M-currents. Fig. 7E shows
pooled data, illustrating the effects of each individual group tested, in
which JWH133 (1 μM) enhanced M-currents (n = 19 from 8 mice, p
= 0.0002, paired t-test), AM630 + JWH133 abolished JWH133's effect,
retigabine enhanced but XE991 reduced M-currents in WT mice. While
in CB2−/−mice, JWH133 failed to enhance M-current but retigabine still
enhances andXE991 still reducedM-currents. These results suggest that
the inhibitory effect of JWH133 on M-current is mediated through the
CB2Rs, while the effects of retigabine and XE991 on M-current are
CB2R-independent.
3.7. Roles of CB2R-mediated enhancement of M-current in altered VTA DA
neuron ﬁring
To further determine whether JWH133-enhanced M-currents con-
tribute to JWH133-induced VTA DA neuronal inhibition, we examined
the effects of retigabine and XE991 on VTA DA neuronal ﬁring. In single
dissociated VTA DA neurons, we found that retigabine (10 μM) in-
creased M-currents, in an amplitude similar to JWH133, causing a re-
duction in VTA DA neuronal ﬁring, while XE991 (30 μM) attenuated
M-currents, producing an increase in neuronal ﬁring (Fig. 8A, B).
Fig. 8C and D show the summarized results after statistical analyses
that retigabine reduced AP ﬁring rate and prolonged AP initial time,
and XE991 increased AP ﬁring rate and shorted AP initial time. These re-
sults suggest that M-current in VTA DA neurons play an important role
inmodulation of neuronalﬁring rate. InVTA slices, cell-attached record-
ings showed that, in the presence of XE991, JWH133 failed to inhibit DA
neuron ﬁring (Fig. 8E, F). These results suggest that JWH133-enhanced
M-currents play a role in the JWH133-induced reduction in VTA DA
neuronal ﬁring.
3.8. Intracellular signal pathway of JWH133-induced enhancement of
M-current
In these experiments, we determinedwhich secondmessengermol-
ecule mediates the CB2R-G-protein signaling to M-type K+ channels. It
is known that CB2R activation primarily initiates two signal pathways,
MAPK/ERK and cAMP/PKA, producing an increase in the former and de-
crease in the latter [37–39]. Since cAMP, but not MAPK, is associated to
M-type K+ channels [37,40], we examined the effect of enhanced intra-
cellular cAMP by forskolin on JWH133-induced enhancement of M-
current. As shown in Fig. 9, bath-perfusion of 10 μM forskolin to dissoci-
ated single VTADAneuron reducedM-current by 19.2±4.9% and in the
presence of forskolin, JWH133 (1 μM) potentiated M-current by 8.1 ±
3.7% (n = 10 from 5 mice, One-Way ANOVA, F [3,27]=14.9, p b
0.0001). Further analysis showed that forskolin-induced reduction of
M-current was signiﬁcant (p b 0.01, One-way ANOVA, Tukey), while
in the presence of forskolin, JWH133-induced change of AP ﬁring was
Fig. 6. Analysis of CB2R-mediated changes of action potential (AP) in dissociated VTA DA neurons. Representative typical traces of AP of VTA DA neurons before (a), during (b) and after
(c) exposure of 1 μM JWH133 under perforated current-clamp recording conditions. APﬁringwas elicited by injection of 10 pA current through recording electrode. Superimposed theﬁrst
AP from trace (a)-(c) to show theAP initiation (d) andAPafter-hyperpolarization (e)with expended time scale. (f)Normalized data showing the effect of JWH133 onAPﬁringparameters.
* p b 0.05, ** p b 0.01.
Fig. 7. Effects of JWH133 onM-type K+ currents in single dissociated VTADAneurons. (a)-(c) Representative typical traces of M-currents before, during and after exposure of JWH133.M-
currents were induced by a pre-depolarization from holding potential of−60 mV to−30 mV, then three steps back to−60 mV in 10 mV increments. Fig. 6b illustrates that JWH133
increased M-current amplitude in VTA DA neurons. (d) Superimposed M-current before (Black trace) and during (red trace) JWH133 exposure with expanded time scale. (e) Bar
graph illustrating that JWH133 (1 μM) enhanced M-currents, which was blocked by AM630 or absent in CB2−/−mice. Retigabine enhanced, while XE991 attenuated M-currents in both
WT and CB2−/−mice. The above experiments were performed separately by each paired (before and after tested drug exposure) group. In statistical analyses, the baseline (before drug
exposure) was normalized as 1, and the changed value after drug perfusion was compared to the baseline of each individual group, and analyzed using paired t-test.
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Fig. 8. Roles of M-type K+ currents in JWH133-modulated VTA DA neuron ﬁring. (a) Representative typical traces of M-type K+ currents in control (top trace), retigabine (middle trace)
and XE991 (bottom trace) from the same acutely-dissociated neuron, and showed that retigabine enhanced and XE991 reducedM-current. (b) Representative typical traces of APﬁring in
control (top trace), retigabine (middle trace) and XE991 (bottom trace) from the same recorded neuron, and showed that retigabine decreased and XE991 increased AP ﬁring rate.
(c) Statistical analysis of the effects of retigabine on VTA DA neuronal AP ﬁring including ﬁring rate (FR), resting membrane potential (RP) and AP initial time. AP ﬁring was evoked by
an injection of depolarizing current (20 pA). (d) Statistical analysis of the effects of XE991 on VTA DA neuronal AP ﬁring including ﬁring rate (FR), resting membrane potential (RP)
and AP initial time. AP ﬁring was evoked by an injection of depolarizing current (20 pA). (e) In VTA slices using cell-attached recording, the time-frequency histograph showed no
detectable change of AP ﬁring rate after exposure to XE991 plus JWH133. (f) Statistical analysis showed JWH133 failed to reduce VTA DA ﬁring rate in the presence of XE991.
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sults suggest that CB2R-mediated reduction of intracellular cAMP likely
contributes to the enhancement of M-current by JWH133. Finally, we
determinedwhether forskolin can prevent the JWH133-induced DA ﬁr-
ing reduction. As shown in Fig. 9C and D, using cell-attached recording
in VTA slices, bath-application of forskolin (10 μM) increased DA ﬁring
rate and prevented JWH133 (10 μM)-mediated reduction of DA ﬁring
rate (n= 11 from 5 mice, One-way ANOVA, F [2,20] = 4.63, p= 0.018,
Fig. 9C, D). Further analysis showed that forskolin increased AP ﬁring
rate by 8.2 ± 2.0% (p b 0.05, paired t-test), while in the presence of
forskolin, JWH133 altered AP ﬁring by 1.2 ± 3.0% (p N 0.05, paired t-
test). Together, these results suggest that JWH133 activates CB2R-G-
protein signaling, thereby reducing intracellular cAMP levels, in turnenhancing M-type K+ channel function, and ultimately reducing VTA
DA neuronal excitability.
3.9. Do both synaptic and intrinsic mechanisms contribute to CB2R-
mediated reduction of VTA DA neuron ﬁring?
To further determine the above ﬁndings that presynaptic mecha-
nism (reduced mEPSC frequency) and intrinsic mechanism (enhanced
M-current) contribute to CB2R-mediated inhibition in VTA DA neuronal
ﬁring, we designed two additional experiments. First, we examined the
effects of JWH133 on neuronal ﬁring in the presence of NBQX (10 μM),
APV (50 μM) and picrotoxin (100 μM) to block excitatory and inhibitory
presynaptic transmissions.We found that under cell-attached recording
Fig. 9. Effects of forskolin on JWH133 modulated M-current and AP ﬁring in VTA DA neurons. (a) Representative the typical traces of M-current under four different conditions: control
(control, red trace), forskolin (Forsk, green trace), forskolin plus JWH133 (blue trace) and washout of drugs (light blue trace). The enhanced inset showed a reduction of M-current by
forskolin. (b) Statistical analysis showed that forskolin signiﬁcantly reduced M-current and in the presence of forskolin, JWH133 failed to enhance M-current. (c) In VTA slices using
cell-attached recording, a time-frequency histograph showed AP ﬁring rate's change during exposure to forskolin (10 μM) and forskolin plus JWH133 (10 μM). (d) Statistical analysis
showed that forskolin increased AP ﬁring rate, and in the presence of forskolin, JWH133 failed to reduce AP ﬁring rate.
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rate (inhibitory rate was 11 ± 2%, n = 21 from 6 mice, p = 0.0001,
paired t-test, Fig. 10A), while without this pharmacological cocktail,
JWH133-induced reduction in AP ﬁring rate was 18 ± 4% (n = 21
from 8mice, p=0.0002, Fig. 10B). Although the block of synaptic trans-
mission did reduce the inhibitory rate by JWH133 from 18± 4% (with-
out synaptic block) to 11 ± 2% (with synaptic block), the difference of
the inhibitory rate between these two groups (18 ± 4% vs. 11 ± 2%)
was not statistical signiﬁcant (p=0.165, unpaired t-test). These results
suggest that JWH133-induced mild reduction of presynaptic glutamate
release seems not to play an important role in the mediation of
JWH133-induced reduction in DA neuron ﬁring. Second, we selectively
blocked postsynaptic CB2R-G protein function by addition of 600 μM
GDP-β-S, an intracellular G-protein blocker, into the recording elec-
trode, thus allowing GDP-β-S to infuse into the recorded neuron after
converted into whole-cell recording mode. As shown in Fig. 10, in the
presence of intracellular GDP-βS, bath application of 10 μM JWH133
failed to alter AP ﬁring rate in VTA DA neurons (from 1.97 ± 0.39 to
2.03 ± 0.44 Hz, p = 0.44, paired t-test, n = 7 from 3 mice, Fig. 10C).
However, in the absence of intracellular GDP-βS, bath application of
10 μM JWH133 reduced VTA DA neuronal rate (from 1.99 ± 0.23 to
1.70 ± 0.22 Hz, p = 0.004, paired t-test, n = 14 from 4 mice,
Fig. 10D). Statistical analysis showed that under whole-cell recording
conditions (within 5min after converted intowhole-cell conﬁguration),
JWH133 failed to reduce AP ﬁring rate in the presence of intracellular
GDP-βS (Fig. 10E), while JWH133 reduced AP ﬁring in the group neu-
rons that did not contain intracellular GDP-βS (Fig. 10F). These results
suggest that the intrinsic mechanism (CB2R-mediated enhancement of
M-current) predominantly underlies the JWH133-induced reduction
of VTA DA neuron excitability.
4. Discussion
In this study, we ﬁnd that acute exposure of the CB2R agonist,
JWH133, reduces DA neuronal excitability in the VTA, which is mainly
mediated through an intrinsic mechanism. Although JWH133 mildlyreduces presynaptic glutamate release probability and results in a de-
creased glutamatergic synaptic transmission in VTA DA neurons, this
may play little role in JWH133-induced reduction of VTA DA neuron ﬁr-
ing because pharmacological block of synaptic transmission fails to pre-
vent JWH133induced inhibitory effect. JWH133 activates a postsynaptic
CB2R-Gi/o signaling cascade, reduces intracellular cAMP levels, in turn
enhances M-type K+ channel function, and leading to the reduction of
VTA DA neuronal excitability. Through this intrinsic mechanism, CB2Rs
signiﬁcantly reduce VTA DA neuronal excitability, which may underlie
CB2R-mediated modulations in mesolimbic DA system function and
DA-related behavior and diseases.
VTA DA neuronal ﬁring is controlled by excitatory and inhibitory
synaptic innervations. Modulations of these synaptic inputs alter neuro-
nal excitability. Numerous G-protein-coupled receptors such as opioid,
5-HT2, metabolic glutamate, GABAB and CB1 receptors modulate synap-
tic transmission by alteration of presynaptic neurotransmitter release.
Emerging evidence demonstrates that activation of CB2Rs modulates
synaptic transmission in the entorhinal cortex [41], transfected hippo-
campal Duald neurons [42] and hippocampal pyramidal neurons from
hippocampal slice cultures [43]. Thus, it is reasonable that CB2Rs are
expressed in presynaptic terminals/boutons and modulate neurotrans-
mitter release. Indeed, in this study, we found a mild, but statistically
signiﬁcant, reduction in the frequency of mEPSC after exposure to
JWH133 (10 μM), suggesting that JWH133-induced reduction in VTA
DA neuronal excitabilitymay bemediated, at least in part, through a re-
duction of glutamatergic synaptic transmission onto DA neurons. How-
ever, additional experiments showed that pharmacological block of
glutamatergic and GABAergic transmissions by perfusion of NBQX,
APV and picrotoxin to VTA slice failed to prevent JWH133 (10 μM)-
induced reduction in DA neuron ﬁring rate. These results suggest that
JWH133-induced the mild reduction of presynaptic glutamate release
does not contribute to the JWH133-induced reduction in DA neuron ﬁr-
ing under our experimental conditions. Previous report has shown that
the activation of CB2Rs reduced inhibitory synaptic transmission in the
entorhinal cortex [41], but this study did not identify the cellular loca-
tion of the CB2Rs involved [41]. Thus, the pharmacological effects
Fig. 10. Determination of the role of synaptic and intrinsic mechanisms in JWH133-
induced reduction of VTA DA neuronal excitability. (a) Bar graph summarizes data that
showed the alteration of AP ﬁring rate before and after JWH133 exposure. The VTA DA
neuron AP ﬁring was recorded using cell-attach recording mode in the presence (a) and
absence (b) of and of cocktail pharmacology (NBQX+APV + PTX) to block synaptic
transmission. (c) Representative typical traces showing the AP ﬁring measured by
whole-cell recordings in current-clamp mode before (left) and after (right) JWH133
exposure. In these experiments, the GDP-βS (600 μM) was added into recording
electrode, and converted to whole-cell recording mode allowed GDP-βS infusion into
recorded cells, and data showed that JWH133 failed to alter AP ﬁring rate.
(d) Representative typical traces in control group showing the AP ﬁring measured by
whole-cell recordings in current-clamp mode before (left) and after (right) JWH133
exposure without GDP-βS in the pipette solution and showed that JWH133 reduced AP
ﬁring rate. (e)/(f) Bar graph summarizes pooled data from (c) and (d) demonstrating
that JWH133 signiﬁcantly reduced AP ﬁring rate in control (d), but not GDP-βS-treated
neurons (c). ** p b 0.01, *** p b 0.001, compared to AP ﬁring before JWH133 exposure.
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microglia [44] since microglia are capable of modulating synaptic plas-
ticity [45]. Another report demonstrated that selective activation of
neuronal CB2Rs reduced inhibitory synaptic transmission via a presyn-
aptic mechanism in transfected hippocampal Duald neurons prepared
from CB1R−/− mice [42]. Compared to these two reports, we found
that CB2Rs mildly reduced glutamatergic, but not GABAergic transmis-
sion in mouse VTA DA neurons. This discrepancy may be due to several
reasons. First, different brain regions or neuronal phenotypes may have
varied levels of CB2R expression [46]. This is supported by our recent
ﬁnding that CB2Rs are highly expressed in themidbrain andmoderately
expressed in the prefrontal cortex (PFC), while the expression in the
striatum is very low [25]. Second, brain CB2R expression is inducible
and dynamic. For example, repeated cocaine administration or self-
administration signiﬁcantly up-regulates brain CB2R expression in the
PFC, striatum and midbrain, as well as VTA neurons in rats [47]. Simi-
larly, chronic, rather than acute, treatment of the slices with JWH133
for 7 days signiﬁcantly enhanced excitatory synaptic transmission,suggesting that chronic treatment of JWH133may up-regulate CB2R ex-
pression in the hippocampus [43]. Third, different CB2R agonists, with
varying pharmacological actions, were used in separate studies. These
pharmacological variances, resulting in the activation of diverse intra-
cellular signal pathways [48], may explain these inconsistent electro-
physiological ﬁndings. Collectively, our data suggest that
glutamatergic presynaptic terminal/boutons may express very low
level of CB2Rs, where theymildly modulate glutamate release probabil-
ity, but contribute little to the alteration of DA neuron ﬁring rate. Inter-
estingly, we did not see a signiﬁcant effect of JWH133 on mIPSCs,
eEPSCs and eIPSCs in VTADAneurons, which is consistentwith previous
report that activation of CB2Rs modulated glutamatergic, but not
GABAergic synaptic, transmission in hippocampal slices [43]. The reason
remains unknown, it may suggest that CB2Rs are mainly distributed on
the neuron somato, and only limited CB2Rs are expressed on gluta-
matergic presynaptic terminals/boutons in VTA DA neurons. Our previ-
ouswork supports this idea [25] aswe showed predominant expression
of CB2Rs on the VTA DAergic cell body.
In addition to presynaptic effect, VTADAneuronal excitability is also
profoundly modulated by intrinsic postsynaptic mechanisms, including
the linkage of G-protein-coupled receptors to ion channels located on
the cell membrane. CB2Rs are G-protein-coupled receptors that, when
activated, alter G-protein (Gi/Go)-coupled intracellular signaling cas-
cades [49]. Emerging lines of evidence suggest that in VTA DA neurons,
G-protein-coupled receptor signaling modulates neuronal excitability
through several types of ion channels, e.g., G-protein-coupled inwardly
rectifying K+ channels (GIRK) [50–52], M-type K+ channels [32,53,54],
A-type of K+ channels [55], and L-type voltage-gated Ca2+ channels
[56]. In the present study, we found that JWH133 reduced neuron ﬁring
in acutely-dissociated VTA DA neurons by prolonging AP initiation, en-
hancing AHP amplitude and hyperpolarizing membrane potential, sug-
gesting a potentiation of M-type K+ current. Under voltage-clamp
mode, we measured M-current in dissociated VTA DA neurons, and
found a CB2R-dependent enhancement of M-current amplitude by
JWH133, conﬁrming that CB2Rs modulate M-current. M-channels are
voltage-gated K+ channels that strongly activate on depolarization to
repolarize the cell, and potently regulate neuronal excitability [57,58].
Since M-type channels are activated at a membrane potential near the
threshold for action potential initiation, it has a strong inﬂuence on neu-
ronal excitability and responsiveness to synaptic inputs [59,60], and
plays a critical role in terminating bursting activity in hippocampal
CA1 neurons [61]. Importantly, under resting physiological conditions,
M-channels are not fully open. Single channel analysis of both native
[53,59] and recombinant [62,63] Kv7.2/Kv7.3 channels demonstrates
that the maximal channel open probability is b1.0, suggesting that
there is a considerable range to fully activateM-channels, and therefore,
regulate neuronal activity. It was reported that VTADA neurons express
M-type K+ channels [32] and these channels play an important role in
controlling VTA DA neuronal excitability [64]. It has been reported
that activation of G-protein-coupled receptors increases M-currents in
hippocampal neurons, by administration of somatostatin [65],
corticostatin [66], or dynorphin [67]. This G-protein-mediated enhance-
ment of M-current is important since it reduces neuronal excitability
and counteracts convulsions. Indeed, it was also reported that the M-
current enhancer, retigabine, shifts the current–voltage curve to the
left (so that the channels open at more hyperpolarized membrane po-
tentials) and increases the maximal opening probability [68,69], there-
fore, producing a strong suppression of neuronal ﬁring [68] and
exhibiting a potent anticonvulsant effect [70].We also compared the ef-
fects of JWH133 and retigabine on M-current and VTA DA neuronal ﬁr-
ing. We found that JWH133 and retigabine enhanced M-current
amplitude and reduced neuronal ﬁring rate. However, in the presence
of M-current blocker (XE991), JWH133 failed to inhibit VTA DA neuron
ﬁring. These results suggest that CB2R-mediated enhancement of M-
current is an important intrinsic mechanism underlying the CB2R-
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examined the signaling between CB2R activation and M-current en-
hancement. Based on the previous studies, activation of CB2Rs primarily
initiates two signal pathways, MAPK/ERK and cAMP/PKA [37–39,48].
Considering cAMP plays an important role in modulation of M-current
[40] and neuronal ﬁring [71,72], we tested whether or not CB2R-
induced reduction of cAMP contributes to the enhanced effect of M-
current. To reach this goal, we applied forskolin, a cAMP enhancer to
the recorded cell to increase intracellular cAMP levels [73]. We tried to
address 3 questions: [1] Does forskolin suppress M-current? [2] Does
forskolin increase VTA DA neuron ﬁring? [3] Does forskolin prevent
JWH133-induced inhibition of VTA DA neuron ﬁring? Our data clearly
showed that forskolin (10 μM) reduced M-current and increased VTA
DA neuron ﬁring. In the presence of forskolin, JWH133 failed to potenti-
ate M-current and reduce AP ﬁring. These results suggest that CB2R-G-
protein-cAMP pathway likely plays a critical role in modulation of M-
current and consequently neuronal excitability. Thus, under our exper-
imental conditions (in vitro preparations), the activation of
somatodendritic CB2Rs on VTA DA neurons reduces intracellular cAMP
levels and enhancesM-current amplitude, leading to a reduction in neu-
ronal ﬁring and excitability. However, in vivo conditions may be more
complex, for example CB2Rs can modulate neuronal excitability by act-
ing on glial cells [74,75], by modulating endogenous cannabinoid sub-
stances or even by acting on peripheral cells.
Our ﬁndings that the CB2R-mediated reduction of VTA DA neuronal
excitability, the underlying intracellular signaling (cAMP) and target
(M-channels) have translational signiﬁcance. Accumulating lines of
evidence demonstrate that CB2Rs mediate a variety of important mod-
ulations in DA-associated behaviors [76] including food intake, body
weight [77–80], depression [81], anxiety [14,82], and schizophrenia-
like behavior [15,83]. Recent reports emerging from several labs, in-
cluding ours, have shown brain CB2Rs play a pivotal role in the elim-
ination of cocaine, alcohol and nicotine addiction [84–86]. These lines
of evidence strongly suggest an important impact of CB2Rs in the
mesocorticolimbic system as well as critical roles in various brain
functions including psychiatric, cognitive and neurobiological activity.
The ﬁnding of the CB2R-mediated reduction of midbrain DA neuronal
excitability provides an insight into understanding of the roles played
by CB2Rs in the above mentioned DA-associated function and diseases.
When compared to CB1Rs, brain CB2Rs exhibit highly translational po-
tential to be used in clinical practices since the following unique fea-
tures: [1] Lower expression levels, suggesting that these receptors
may not mediate the effect of cannabis under normal physiological
conditions; [2] Highly inducible, meaning that under some pathologi-
cal conditions (e.g., addiction, inﬂammation, stroke, schizophrenia,
stress, anxiety, etc.), CB2R expression is enhanced in the brain [87],
suggesting a close relationship between the alteration of CB2R expres-
sion/function and various psychiatric and neurological diseases; and
[3] Exhibit special distribution, given that CB2Rs are chieﬂy expressed
in neuronal somatodendritic areas [8] (postsynaptic) but CB1Rs are
predominantly expressed on neuronal terminals, especially on
GABAergic terminals (presynaptic), which leads to some opposing ef-
fects after activation by these two receptor subtypes [88]. Considering
these characteristic features, the mesolimbic CB2R appears to be an
important substrate for neuroprotection [89], and targeting CB2Rs or
manipulations of their signaling (cAMP/PKA) and target (M-channels)
will likely offer a novel therapeutic strategy for treating neuropsychi-
atric and neurological diseases without typical CB1R-mediated side-
effects.
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